Clinical overview of MDM2/X targeted therapies

Clinical overview of MDM2/X targeted therapies

MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions, maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation, and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly o...

Full description

Bibliographic Details
Main Authors: Andrew eBurgess, Kee Ming Chia, Sue eHaupt, David eThomas, Ygal eHaupt, Elgene eLim
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-01-01
Series:Frontiers in Oncology
Subjects:
cancer therapy
p53
MDM2
MDMX
Nutlin 3a
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00007/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00007/full

Similar Items